P Pradat

Summary

Country: France

Publications

  1. ncbi request reprint Progression to cirrhosis in hepatitis C patients: an age-dependent process
    Pierre Pradat
    Department of Hepatogastroenterology, Hotel Dieu, Lyon, France
    Liver Int 27:335-9. 2007
  2. ncbi request reprint Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications
    P Pradat
    Hospices Civils de Lyon, Universite Claude Bernard Lyon 1, Lyon, France
    J Viral Hepat 14:556-63. 2007
  3. ncbi request reprint Prevalence of hepatitis C infection among general practice patients in the Lyon area, France
    P Pradat
    Department of Hepatology, Hotel Dieu, Lyon, France
    Eur J Epidemiol 17:47-51. 2001
  4. ncbi request reprint The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment
    Pierre Pradat
    Department of Hepatology, Hotel Dieu, Lyon, France
    J Med Virol 73:392-6. 2004
  5. ncbi request reprint [Medical follow-up of patients with positive serology for hepatitis C virus]
    F Sahajian
    ADHEC, , , Domaine Rockefeller, Lyon, France
    Gastroenterol Clin Biol 25:262-7. 2001
  6. ncbi request reprint Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection posttransplantation
    T Bizollon
    Unité d Hépatologie et de Transplantation hépatique, Groupement Hospitalier du Nord HCL, Lyon, France
    Am J Transplant 7:448-53. 2007
  7. ncbi request reprint Clinical relevance of total HCV core antigen testing for hepatitis C monitoring and for predicting patients' response to therapy
    M Maynard
    Department of Hepatology, Hotel Dieu, Lyon, France
    J Viral Hepat 10:318-23. 2003
  8. doi request reprint Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate
    P Pradat
    Hospices Civils de Lyon, Hopital de la Croix Rousse, Service d Hepatologie, Lyon, France
    J Viral Hepat 20:650-7. 2013
  9. ncbi request reprint Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients
    Marianne Maynard
    Hospices Civils de Lyon, Hotel Dieu, Service d hépatologie et de gastroentérologie, 69002 Lyon, France
    Antivir Ther 13:607-11. 2008
  10. ncbi request reprint Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C
    Thierry Bizollon
    Hotel Dieu 1, Lyon, France
    Transplantation 79:325-9. 2005

Collaborators

Detail Information

Publications23

  1. ncbi request reprint Progression to cirrhosis in hepatitis C patients: an age-dependent process
    Pierre Pradat
    Department of Hepatogastroenterology, Hotel Dieu, Lyon, France
    Liver Int 27:335-9. 2007
    ..Age at infection is known to be associated with disease progression rate in hepatitis C virus (HCV) infected patients. The aim of this study was to assess when cirrhosis is expected to occur according to host and viral factors...
  2. ncbi request reprint Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications
    P Pradat
    Hospices Civils de Lyon, Universite Claude Bernard Lyon 1, Lyon, France
    J Viral Hepat 14:556-63. 2007
    ..The large proportion of patients lost to follow up stresses the need for a strengthened and optimized management of HCV patients...
  3. ncbi request reprint Prevalence of hepatitis C infection among general practice patients in the Lyon area, France
    P Pradat
    Department of Hepatology, Hotel Dieu, Lyon, France
    Eur J Epidemiol 17:47-51. 2001
    ..To estimate the prevalence of hepatitis C virus (HCV) infection among patients in general practices...
  4. ncbi request reprint The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment
    Pierre Pradat
    Department of Hepatology, Hotel Dieu, Lyon, France
    J Med Virol 73:392-6. 2004
    ..This assay is a new reliable alternative for early prediction of virological non-response in patients treated with pegylated interferon/ribavirin...
  5. ncbi request reprint [Medical follow-up of patients with positive serology for hepatitis C virus]
    F Sahajian
    ADHEC, , , Domaine Rockefeller, Lyon, France
    Gastroenterol Clin Biol 25:262-7. 2001
    ..Treatment was started in 8 patients. CONCLUSION: The results of this study on medical follow-up are satisfying. The general practitioner plays a key role in the follow-up of patients infected by hepatitis C virus...
  6. ncbi request reprint Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection posttransplantation
    T Bizollon
    Unité d Hépatologie et de Transplantation hépatique, Groupement Hospitalier du Nord HCL, Lyon, France
    Am J Transplant 7:448-53. 2007
    ..More interesting is that fibrosis score was improved in 65% of treated patients despite failure of HCV eradication...
  7. ncbi request reprint Clinical relevance of total HCV core antigen testing for hepatitis C monitoring and for predicting patients' response to therapy
    M Maynard
    Department of Hepatology, Hotel Dieu, Lyon, France
    J Viral Hepat 10:318-23. 2003
    ..The determination of total HCV Core Ag levels in serum, constitutes an accurate and reliable alternative to HCV-RNA for monitoring and predicting treatment outcome in patients receiving PEG-IFN/Ribavirin combination therapy...
  8. doi request reprint Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate
    P Pradat
    Hospices Civils de Lyon, Hopital de la Croix Rousse, Service d Hepatologie, Lyon, France
    J Viral Hepat 20:650-7. 2013
    ..Regular follow-up of renal function, especially tubular function is recommended during TDF therapy...
  9. ncbi request reprint Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients
    Marianne Maynard
    Hospices Civils de Lyon, Hotel Dieu, Service d hépatologie et de gastroentérologie, 69002 Lyon, France
    Antivir Ther 13:607-11. 2008
    ..The aim of this study was to define the ribavirin trough plasma concentration at week 4 (W4) associated with sustained virological response (SVR)...
  10. ncbi request reprint Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C
    Thierry Bizollon
    Hotel Dieu 1, Lyon, France
    Transplantation 79:325-9. 2005
    ..However, the optimal therapy for nonresponders remains an unresolved issue. We conducted a pilot study to determine the efficacy and safety of triple antiviral therapy in IFN-ribavirin nonresponders with recurrent chronic hepatitis C...
  11. doi request reprint Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV/HBV-coinfected patients
    P Miailhes
    Hospices Civils de Lyon, Hopital Hotel Dieu, Service d Hepatogastroenterologie, Lyon, France
    J Viral Hepat 18:61-9. 2011
    ..In HIV/HBV-coinfected patients, most of them with normal ALT under antiretroviral treatment including HBV active drugs, TE was proficient in discriminating moderate to severe fibrosis from minimal liver disease...
  12. ncbi request reprint Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Co-operative Research
    S Touzet
    Département d information médicale, Hospices Civils de Lyon, France
    Eur J Gastroenterol Hepatol 12:667-78. 2000
    ..Multicentre studies conducted in larger samples are needed to obtain more accurate and reliable results, in particular. However, the epidemiological studies available allowed us to assess the magnitude of HCV infection in Europe...
  13. ncbi request reprint Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C
    Thierry Bizollon
    Hotel Dieu, Lyon, France
    Am J Transplant 5:1909-13. 2005
    ..009). No difference in patient survival was observed in the two groups. In conclusion, this study shows that HCV eradication has a positive impact on graft survival...
  14. doi request reprint In vivo infectivity of liver extracts after resolution of hepadnaviral infection following therapy associating DNA vaccine and cytokine genes
    F Saade
    Universite de Lyon, Lyon, Lyon, France
    J Viral Hepat 20:e56-65. 2013
    ....
  15. ncbi request reprint Hepatitis C virus infection in Western Europe
    C Trepo
    Department of Hepato Gastroenterology, Hotel Dieu, Lyon, France
    J Hepatol 31:80-3. 1999
    ..Further training and information campaigns remain desirable to improve knowledge and awareness among health care professionals...
  16. ncbi request reprint Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study
    Pierre Pradat
    Department of Hepatology, Hotel Dieu, Lyon, France
    Hepatology 36:973-7. 2002
    ..In this subset of patients, the indication of liver biopsy and the potential benefit of therapy need to be further evaluated. These results suggest the need to revisit the algorithm for liver biopsy practice...
  17. doi request reprint Association of anti-E1E2 antibodies with spontaneous recovery or sustained viral response to therapy in patients infected with hepatitis C virus
    Ndiémé Ndongo
    Institut National de la Sante et de la Recherche Medicale INSERM, Unit 871, Molecular Physiopathology and New Therapies in Viral Hepatitis, Lyon, France
    Hepatology 52:1531-42. 2010
    ..One month prior to therapy initiation, the threshold of 1131 (optical density × 1000) gave 100% and 86% positive and negative predictive values, respectively, for achieving or not achieving a sustained viral response...
  18. ncbi request reprint Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion
    Patrick Miailhes
    Hotel Dieu, Service d hépatologie et de gastroentérologie, Lyon, France
    Clin Infect Dis 45:624-32. 2007
    ....
  19. doi request reprint Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 16 cases
    Jean Francois Dufour
    Department of Internal Medicine, University Claude Bernard, Lyon 1, Lyon, France
    Eur J Gastroenterol Hepatol 21:245-53. 2009
    ..To describe the prevalence, main characteristics, and treatment of severe autoimmune cytopenias [autoimmune hemolytic anemia (AIHA), autoimmune thrombocytopenic purpura (AITP)] in patients with chronic hepatitis C virus (HCV) infection...
  20. doi request reprint Management of nonresponsive hepatitis C
    François Bailly
    INSERM, U871, Lyon, France
    Expert Rev Anti Infect Ther 8:379-95. 2010
    ....
  21. ncbi request reprint Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI)
    Marianne Maynard
    Department of Hepato Gastroenterology, Hotel Dieu, 1 Place de l Hopital, 69288 Lyon Cedex 02, France
    J Hepatol 44:484-90. 2006
    ..To determine whether addition of amantadine to pegylated interferon/ribavirin improved response rates among chronic hepatitis C patients, non-responders to interferon/ribavirin and study the dynamic of response...
  22. doi request reprint DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection
    Alexandre Thermet
    INSERM, Unit 871, F 69424 Lyon, France
    J Gen Virol 89:1192-201. 2008
    ..These results also highlight the importance of antiviral drug potency and an effective DNA immunization protocol for the design of therapeutic vaccines against chronic hepatitis B...
  23. doi request reprint Human papillomavirus genotype distribution in low-grade squamous intraepithelial lesions in France and comparison with CIN2/3 and invasive cervical cancer: the EDiTH III study
    Jean Luc Pretet
    EA3181, IFR133, Universite de Franche Comte, Besancon, France
    Gynecol Oncol 110:179-84. 2008
    ....